한글목차

종양 바이오마커 시장 규모는 최근 빠르게 확대하고 있습니다. 2025년 173억 달러에서 2026년에는 197억 3,000만 달러로, CAGR 14.1%로 성장할 것으로 예상됩니다. 지난 몇 년간의 성장은 암 검진 프로그램 확대, 분자생물학 연구의 발전, 바이오마커 검사 플랫폼의 가용성 향상, 종양학 임상시험의 증가, 연구기관과 병원 간의 협력 강화에 기인한 것으로 보입니다.

종양 바이오마커 시장 규모는 향후 몇 년간 급속한 성장이 전망됩니다. 2030년에는 336억 3,000만 달러에 달하고, CAGR은 14.3%를 기록할 전망입니다. 예측 기간 동안의 성장은 맞춤형 암 치료에 대한 수요 증가, AI 기반 바이오마커 발견 확대, 암 유전체학에 대한 투자 증가, 액체 생검 기술 채택 확대, 조기 암 발견 및 모니터링에 대한 집중 강화에 기인할 것으로 예상됩니다. 예측 기간의 주요 동향으로는 정밀 암 진단의 채택 확대, 유전자 및 단백질 바이오마커의 사용 증가, 바이오인포매틱스를 바이오마커 분석에 통합하는 움직임의 확대, 동반진단 개발 확대, 맞춤형 암 치료에 대한 집중도 강화 등이 있습니다.

암 발생률의 증가는 종양 바이오마커 시장의 성장을 견인할 것으로 예상됩니다. 암은 통제할 수 없는 세포 증식이 특징이며, 점차 전신으로 퍼질 수 있습니다. 종양 바이오마커는 환자의 유전자, 단백질, 기타 생물학적 물질을 분석하여 암의 종류에 대한 정보를 제공합니다. 예를 들어, 2024년 2월 스위스에 본부를 둔 국제기구인 세계보건기구(WHO)는 2050년까지 신규 암 발병 건수가 3,500만 건을 넘어설 것으로 예측했습니다. 이는 2022년 추정치인 2,000만 건에서 77% 증가한 수치입니다. 이러한 암 부담의 증가는 종양학 바이오마커 시장의 확대를 뒷받침하고 있습니다.

종양 진단 시장의 주요 기업들은 암 조기 발견, 미세잔존병변(MRD) 모니터링, 치료에 대한 환자 반응 평가를 위한 첨단 바이오마커 기반 검사법 개발에 주력하고 있습니다. MRD는 치료 후에도 남아있을 수 있는 소량의 암세포를 말하며, 발견되지 않으면 재발을 유발할 수 있습니다. 예를 들어, 2024년 5월 미국의 인공지능 및 정밀의료 기업 템패스(Tempus)는 퍼스널리스(Personalis)가 개발한 xM 테스트 및 xM(NeXT Personal Dx) 테스트를 포함한 MRD 검사 포트폴리오를 발표하였습니다. 이 제품군은 종양 미치료 환자 및 종양 정보를 활용한 검사를 특징으로 하며, 암 재발 및 잔존 병변을 조기에 발견할 수 있고, 면역치료에 대한 반응을 모니터링할 수 있습니다. 순환 종양 바이오마커를 활용함으로써 이러한 검사는 임상의에게 민감하고 실용적인 정보를 제공하여 환자 관리의 지침이 될 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Oncology biomarkers are biological indicators, such as genes, proteins, or other molecules, that can indicate the presence of cancer or its progression. They play a crucial role in diagnosing cancer, predicting treatment responses, and monitoring disease progression or recurrence. By analyzing these biomarkers, healthcare providers can create personalized treatment plans tailored to individual patients.

The primary categories of oncology biomarkers include protein biomarkers, genetic biomarkers, and others. Protein biomarkers involve the use of one or multiple proteins for diagnosing diseases, understanding prognosis, and monitoring a patient's biological response to treatment. Profiling technologies encompass omics technologies, imaging technologies, immunoassays, bioinformatics, and others. Cancer types covered by oncology biomarkers include breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, ovarian cancer, liver cancer, and others. These biomarkers find various applications such as diagnostics, research and development, prognostics, risk assessment, and more, predominantly utilized in hospitals, academic and cancer research institutes, ambulatory surgical centers, and diagnostic laboratories.

Tariffs are impacting the oncology biomarkers market by increasing costs of imported reagents, assay kits, sequencing instruments, imaging systems, and analytical software tools. Diagnostic laboratories and research institutions in North America and Europe are most affected due to dependence on imported high-end technologies, while Asia-Pacific faces cost pressure on biomarker kit exports. These tariffs are increasing testing costs and research budgets. However, they are also encouraging local assay development, regional manufacturing of diagnostic kits, and investment in domestic biomarker research infrastructure.

The oncology biomarkers market research report is one of a series of new reports from The Business Research Company that provides oncology biomarkers market statistics, including oncology biomarkers industry global market size, regional shares, competitors with a oncology biomarkers market share, detailed oncology biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biomarkers industry. This oncology biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology biomarkers market size has grown rapidly in recent years. It will grow from $17.3 billion in 2025 to $19.73 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to expansion of cancer screening programs, advancements in molecular biology research, increased availability of biomarker testing platforms, growth in oncology clinical trials, rising collaboration between research institutions and hospitals.

The oncology biomarkers market size is expected to see rapid growth in the next few years. It will grow to $33.63 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing demand for personalized oncology therapies, expansion of AI-driven biomarker discovery, growing investments in cancer genomics, rising adoption of liquid biopsy technologies, increased focus on early cancer detection and monitoring. Major trends in the forecast period include increasing adoption of precision oncology diagnostics, rising use of genetic and protein biomarkers, growing integration of bioinformatics in biomarker analysis, expansion of companion diagnostics development, enhanced focus on personalized cancer treatment.

The rising incidence of cancer is expected to drive growth in the oncology biomarker market. Cancer is characterized by the uncontrolled growth of cells that can gradually spread throughout the body. Oncological biomarkers offer insights into cancer type by analyzing genes, proteins, and other biological substances in the patient. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, representing a 77% increase from an estimated 20 million cases in 2022. This rising cancer burden is therefore supporting the expansion of the oncology biomarkers market.

Major companies in the oncology diagnostics market are focusing on developing advanced biomarker-based assays to enhance early cancer detection, monitor minimal residual disease (MRD), and evaluate patient responses to therapy. MRD refers to the small number of cancer cells that may remain after treatment and could cause recurrence if undetected. For example, in May 2024, Tempus, a US-based artificial intelligence and precision medicine company, launched its MRD test portfolio, including the xM test and xM (NeXT Personal Dx) test developed by Personalis. The portfolio features tumor-naive and tumor-informed assays capable of detecting early cancer recurrence and residual disease, while also monitoring responses to immunotherapy. By leveraging circulating tumor biomarkers, these assays provide clinicians with sensitive, actionable insights to guide patient management.

In May 2023, Freenome, a US-based biotech company, completed the acquisition of Oncimmune Ltd., a UK-based company specializing in developing immunodiagnostics. This strategic acquisition is poised to enhance Freenome's cancer screening efforts by providing additional clinical and commercial resources. Moreover, it will contribute to augmenting Freenome's multi-omics platform, offering a more comprehensive view of the tumor microenvironment.

Major companies operating in the oncology biomarkers market are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Agendia Inc., Epigenomics AG, OncoDNA SA

North America was the largest region in the oncology biomarkers market in 2025. The regions covered in the oncology biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oncology biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The oncology biomarkers market consists of sales of epigenetic biomarkers, metabolic biomarkers and proteomic biomarkers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Biomarkers Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oncology biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Biomarker Type: Protein Biomarkers; Genetic Biomarkers; Other Biomarker Types
• 2) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Leukemia; Ovarian Cancer; Liver Cancer; Other Cancer Types
• 3) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment; Other Applications
• 4) By End-User: Hospitals; Academic And Cancer Research Institutes; Diagnostic Laboratories
• Subsegments:
• 1) By Protein Biomarkers: Tumor-Specific Antigens; Circulating Tumor Cells (CTCs); Enzymatic Biomarkers
• 2) By Genetic Biomarkers: DNA Mutations; Gene Expression Profiles; Single Nucleotide Polymorphisms (SNPs)
• 3) By Other Biomarker Types: Metabolomic Biomarkers; Epigenetic Biomarkers; MicroRNA Biomarkers
• Companies Mentioned: F Hoffmann-La Roche AG; Novartis AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Merck KGaA; Siemens Healthcare GmbH; Becton Dickinson and Company; GE Healthcare Technologies Inc.; Eurofins Scientific SE; Agilent Technologies Inc.; Hologic Inc.; Illumina Inc.; bioMerieux SA; Bio-Rad Laboratories Inc.; Bruker Corporation; QIAGEN NV; Exact Sciences Corporation; Sysmex Corporation; PerkinElmer Inc.; Leica Biosystems; Myriad Genetics Inc.; Guardant Health Inc.; Enzo Biochem Inc.; Biocartis Group NV; Agendia Inc.; Epigenomics AG; OncoDNA SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Oncology Biomarkers Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Oncology Biomarkers Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Oncology Biomarkers Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Oncology Biomarkers Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics And Precision Medicine
  • 4.1.2 Artificial Intelligence And Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data And Cybersecurity
  • 4.1.4 Industry 4.0 And Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure And Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Precision Oncology Diagnostics
  • 4.2.2 Rising Use Of Genetic And Protein Biomarkers
  • 4.2.3 Growing Integration Of Bioinformatics In Biomarker Analysis
  • 4.2.4 Expansion Of Companion Diagnostics Development
  • 4.2.5 Enhanced Focus On Personalized Cancer Treatment

5. Oncology Biomarkers Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Academic And Cancer Research Institutes
• 5.3 Diagnostic Laboratories
• 5.4 Ambulatory Surgical Centers
• 5.5 Pharmaceutical And Biotechnology Companies

6. Oncology Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oncology Biomarkers Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Oncology Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Oncology Biomarkers Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Oncology Biomarkers Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Oncology Biomarkers Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oncology Biomarkers Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oncology Biomarkers Market Segmentation

• 9.1. Global Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types
• 9.2. Global Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types
• 9.3. Global Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
• 9.4. Global Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Academic And Cancer Research Institutes, Diagnostic Laboratories
• 9.5. Global Oncology Biomarkers Market, Sub-Segmentation Of Protein Biomarkers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers
• 9.6. Global Oncology Biomarkers Market, Sub-Segmentation Of Genetic Biomarkers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)
• 9.7. Global Oncology Biomarkers Market, Sub-Segmentation Of Other Biomarker Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

10. Oncology Biomarkers Market Regional And Country Analysis

• 10.1. Global Oncology Biomarkers Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Oncology Biomarkers Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oncology Biomarkers Market

• 11.1. Asia-Pacific Oncology Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oncology Biomarkers Market

• 12.1. China Oncology Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oncology Biomarkers Market

• 13.1. India Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oncology Biomarkers Market

• 14.1. Japan Oncology Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oncology Biomarkers Market

• 15.1. Australia Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oncology Biomarkers Market

• 16.1. Indonesia Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oncology Biomarkers Market

• 17.1. South Korea Oncology Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oncology Biomarkers Market

• 18.1. Taiwan Oncology Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oncology Biomarkers Market

• 19.1. South East Asia Oncology Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oncology Biomarkers Market

• 20.1. Western Europe Oncology Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oncology Biomarkers Market

• 21.1. UK Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oncology Biomarkers Market

• 22.1. Germany Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oncology Biomarkers Market

• 23.1. France Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oncology Biomarkers Market

• 24.1. Italy Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oncology Biomarkers Market

• 25.1. Spain Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oncology Biomarkers Market

• 26.1. Eastern Europe Oncology Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oncology Biomarkers Market

• 27.1. Russia Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oncology Biomarkers Market

• 28.1. North America Oncology Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oncology Biomarkers Market

• 29.1. USA Oncology Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oncology Biomarkers Market

• 30.1. Canada Oncology Biomarkers Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oncology Biomarkers Market

• 31.1. South America Oncology Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oncology Biomarkers Market

• 32.1. Brazil Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oncology Biomarkers Market

• 33.1. Middle East Oncology Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oncology Biomarkers Market

• 34.1. Africa Oncology Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Oncology Biomarkers Market, Segmentation By Biomarker Type, Segmentation By Cancer Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oncology Biomarkers Market Regulatory and Investment Landscape

36. Oncology Biomarkers Market Competitive Landscape And Company Profiles

• 36.1. Oncology Biomarkers Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Oncology Biomarkers Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Oncology Biomarkers Market Company Profiles
  • 36.3.1. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

37. Oncology Biomarkers Market Other Major And Innovative Companies

• Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems

38. Global Oncology Biomarkers Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oncology Biomarkers Market

40. Oncology Biomarkers Market High Potential Countries, Segments and Strategies

• 40.1 Oncology Biomarkers Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Oncology Biomarkers Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Oncology Biomarkers Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer